IGC Pharma (FRA:IGS1) Cyclically Adjusted FCF per Share: €-0.15 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IGS1 IGC Pharma Inc FRA:IGS1
33 GF Score
Price €0.23
GF Value €0.21
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Cyclically Adjusted FCF per Share?

IGC Pharma FRA:IGS1 -1.72% 33 Cyclically Adjusted FCF per Share is €-0.15 as of Mar. 2026. GuruFocus rates FRA:IGS1 with a GF Score™ of 33/100 and a GF Value™ of €0.21 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

IGC Pharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.012. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.15 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of IGC Pharma was 48.90% per year. The lowest was 11.10% per year. And the median was 39.15% per year.

As of today (2026-07-28), IGC Pharma's current stock price is €0.228. IGC Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.15. IGC Pharma's Cyclically Adjusted Price-to-FCF of today is .


IGC Pharma  (FRA:IGS1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


IGC Pharma Cyclically Adjusted FCF per Share Related Terms


IGC Pharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for IGC Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma Cyclically Adjusted FCF per Share Chart

IGC Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 -0.15 -0.17 -0.17 0.00

IGC Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.14 -0.15 -0.15 -0.15

FRA:IGS1 vs ATNM, ACTU, KYNB: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, IGC Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Cyclically Adjusted Price-to-FCF falls into.


FRA:IGS1
33GF Score
IGC Pharma Inc FRA:IGS1
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IGC Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IGC Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.012/330.2130*330.2130
=-0.012

Current CPI (Mar. 2026) = 330.2130.

IGC Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.008 241.018 0.011
201609 -0.033 241.428 -0.045
201612 0.002 241.432 0.003
201703 -0.043 243.801 -0.058
201706 -0.018 244.955 -0.024
201709 -0.008 246.819 -0.011
201712 -0.015 246.524 -0.020
201803 -0.023 249.554 -0.030
201806 -0.015 251.989 -0.020
201809 -0.009 252.439 -0.012
201812 -0.030 251.233 -0.039
201903 -0.026 254.202 -0.034
201906 -0.091 256.143 -0.117
201909 -0.057 256.759 -0.073
201912 -0.089 256.974 -0.114
202003 -0.062 258.115 -0.079
202006 -0.110 257.797 -0.141
202009 -0.057 260.280 -0.072
202012 -0.041 260.474 -0.052
202103 -0.049 264.877 -0.061
202106 -0.034 271.696 -0.041
202109 -0.040 274.310 -0.048
202112 -0.043 278.802 -0.051
202203 -0.026 287.504 -0.030
202206 -0.043 296.311 -0.048
202209 -0.031 296.808 -0.034
202212 -0.036 296.797 -0.040
202303 -0.030 301.836 -0.033
202306 -0.026 305.109 -0.028
202309 -0.029 307.789 -0.031
202312 -0.024 306.746 -0.026
202403 -0.012 312.332 -0.013
202406 -0.024 314.175 -0.025
202409 -0.013 315.301 -0.014
202412 -0.017 315.605 -0.018
202503 0.000 319.799 0.000
202506 -0.016 322.561 -0.016
202509 -0.023 324.800 -0.023
202512 -0.013 324.054 -0.013
202603 -0.012 330.213 -0.012

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.15 mean?
IGC Pharma (FRA:IGS1) has a Cyclically Adjusted FCF per Share of €-0.15 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on IGC Pharma and its competitors.
Is IGC Pharma's Cyclically Adjusted FCF per Share too high?
IGC Pharma's current Cyclically Adjusted FCF per Share is €-0.15. Overall, IGC Pharma has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Cyclically Adjusted FCF per Share compare to ATNM and ACTU?
IGC Pharma's Cyclically Adjusted FCF per Share of €-0.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on IGC Pharma and its competitors. IGC Pharma's current Cyclically Adjusted FCF per Share is €-0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (FRA:IGS1) is currently considered Fairly Valued. The stock's GF Value™ is €0.21, compared to a current price of €0.23 — trading 8.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.15. IGC Pharma's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For IGC Pharma (FRA:IGS1), the current Cyclically Adjusted FCF per Share is €-0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (FRA:IGS1) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of €0.23 is trading 8.6% above its estimated GF Value™ of €0.21. GuruFocus considers IGC Pharma to be Fairly Valued.

Key valuation signals for FRA:IGS1:

  • Cyclically Adjusted FCF per Share: €-0.15
  • GF Value™: €0.21 vs. price of €0.23 (8.6% above fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the FRA:IGS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IGC Pharma Business Description

Other Exchanges IGC:USA
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
33GF Score

Get the complete analysis for FRA:IGS1

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price
€0.21
GF Value